MAR 20, 2020 9:12 AM PDT

4 Potential Treatments for SARS-CoV-2 Currently Under Testing

WRITTEN BY: Annie Lennon

Currently, no medicine nor vaccine has been approved as effective for the prevention of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite this, around the world there are many drugs currently under trial. Here are the top four potential treatments recommended by both Chinese experts and Korean physicians. 

Remdesivir, a novel antiviral drug, is so far a strong candidate. Although results from a clinical trial carried out in China are only expected to become available in April, preclinical trials have shown its efficacy against the virus and that it has a high genetic barrier to resistance. Furthermore, previous data has shown that the drug is able to inhibit activity in other coronavirus strains including the 2002 SARS-CoV and MERS-CoV (Middle Eastern Respiratory Syndrome). 

Sofosbuvir taken in combination with ribavirin is another promising candidate. Although no results from clinical trials are available yet, early results from a molecular docking experiment have shown that the drug combination is able to bind to SARS-CoV-2 molecules. This means that it may also be effective in treating infections caused by the virus. 

Lopinavir, ritonavir taken alongside ribavirin and corticosteroids has also shown promise as a treatment option. Currently being trialed among patients with SARS-CoV-2 who have not developed acute respiratory distress syndrome, results so far look positive. Whereas 6.3% of those being treated with ribavirin and corticosteroids alone died at day 21, with 22.5% meeting the criteria for severe hypoxemia (an abnormally low level of oxygen in the blood), for those treated with lopinavir and ritonavir alongside ribavirin and corticosteroids, just 2.4% met the criteria for severe hypoxemia, whereas none died within the same timeframe.

Interferon alfacon-1 taken together with corticosteroids is another treatment with potential. Under an open-label trial comparing patients with the drug combination and those taking corticosteroids alone, so far, researchers have seen positive results. In particular, those in the interferon alfacon-1 group saw abnormalities in their lungs reduce by 50% in just 4 days, whereas the same took 9 days in the group taking corticosteroids alone. Moreover, the group on interferon alfacon-1 had better oxygen saturation in their blood sooner and thus required supplemental oxygen for significantly less time than those in the control group. Resolutions of fevers however were similar between both groups. 



Sources: El Sevier

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
APR 10, 2020
Cardiology
APR 10, 2020
Drinking Black Tea Reduces Risk of Heart Disease
Black tea is among one of the most commonly consumed beverages around the world. Beyond just being a refreshing and ener ...
APR 13, 2020
Cancer
APR 13, 2020
The Unexpected Role of Mono in Cancer Progression
In the past, the go-to drugs have always been small molecules. These small molecules would interact with the cell and ac ...
APR 16, 2020
Cancer
APR 16, 2020
This drug hopes to prevent cancer relapse
A report published in Nature Communications highlights findings from a study showing that the experimental drug, Qu ...
APR 19, 2020
Drug Discovery & Development
APR 19, 2020
FDA Approves New Drug for Breast Cancer
The US Food and Drug Administration has approved a new drug, known as tucatinib or Tuksya, as a treatment for advanced f ...
APR 21, 2020
Cannabis Sciences
APR 21, 2020
Is CBD Effective Against Women's Health Issues?
Products containing cannabidiol (CBD) are increasingly known as a natural and effective way to handle a wide range of wo ...
MAY 11, 2020
Cancer
MAY 11, 2020
Using Deep Learning to Diagnose Breast Cancer Sub-Types
Cancer and computer programming may not sound like two things that go together. However, advanced programming techniques ...
Loading Comments...